BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21872957)

  • 21. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
    Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
    Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
    Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
    Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
    Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
    Kroenke M; Hirata K; Gafita A; Watanabe S; Okamoto S; Magota K; Shiga T; Kuge Y; Tamaki N
    PLoS One; 2019; 14(2):e0213111. PubMed ID: 30818360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
    Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
    Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
    Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
    Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
    Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.
    Boeke S; Thorwarth D; Mönnich D; Pfannenberg C; Reischl G; La Fougère C; Nikolaou K; Mauz PS; Paulsen F; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1571-1576. PubMed ID: 28891398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images.
    Mönnich D; Troost EG; Kaanders JH; Oyen WJ; Alber M; Zips D; Thorwarth D
    Acta Oncol; 2013 Oct; 52(7):1308-13. PubMed ID: 23984808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
    Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
    Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
    Chang JH; Lim Joon D; Lee ST; Gong SJ; Anderson NJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e691-6. PubMed ID: 22658218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
    Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
    Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors.
    Nishikawa Y; Yasuda K; Okamoto S; Ito YM; Onimaru R; Shiga T; Tsuchiya K; Watanabe S; Takeuchi W; Kuge Y; Peng H; Tamaki N; Shirato H
    Radiat Oncol; 2017 Sep; 12(1):148. PubMed ID: 28877734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations.
    Thorwarth D; Eschmann SM; Paulsen F; Alber M
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):515-21. PubMed ID: 17398015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
    Schütze C; Bergmann R; Brüchner K; Mosch B; Yaromina A; Zips D; Hessel F; Krause M; Thames H; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
    Radiother Oncol; 2014 Apr; 111(1):81-7. PubMed ID: 24636842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
    Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of (immuno-)fluorescence data with serial [¹⁸F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers.
    Maftei CA; Shi K; Bayer C; Astner ST; Vaupel P
    Radiother Oncol; 2011 Jun; 99(3):412-7. PubMed ID: 21719136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [
    Welz S; Paulsen F; Pfannenberg C; Reimold M; Reischl G; Nikolaou K; La Fougère C; Alber M; Belka C; Zips D; Thorwarth D
    Radiother Oncol; 2022 Jun; 171():30-36. PubMed ID: 35395276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT.
    Fatema CN; Zhao S; Zhao Y; Yu W; Nishijima K; Yasuda K; Kitagawa Y; Tamaki N; Kuge Y
    BMC Cancer; 2014 Sep; 14():692. PubMed ID: 25245041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor hypoxia: a new PET imaging biomarker in clinical oncology.
    Tamaki N; Hirata K
    Int J Clin Oncol; 2016 Aug; 21(4):619-625. PubMed ID: 26577447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.